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ABSTRACT 
A previously healthy 33-year-old woman diagnosed with advanced gastric cancer， and 
underwent preoperativ巴 chemotherapywith docetaxel， cisplatin， and S-l (DCS therapy) 
Two DCS courses had finished without h巴avyadverse effects， and then total gastrectomy 
with sple巴nectomyand D2 lymphadenectomy was done， Pathologically， no viable cancer cels 
remained in the primary lesion or dissected lymph nodes， and the pathological response of 
preoperative DCS therapy was judged to be grade 3， She started to treat with S-l postoperative 
adjuvant chemotherapy after one month of gastrectomy， however she could not continue S-l 
chemotherapy because of adverse effects (grade 3 diarrhea and app巴titeloss) ， Now， after 33 
months of op巴ration，she is healthy and being seen as an outpatient without recurrence of gastric 
cancer， (Accepted on November 17， 2014) 


























認めなかった 腫蕩マーカーはCEAl.8 ng/ml， 






























docetaxel 40 mg/rri， cisplatin 60 mgir討をday1


































































レジメン ① ② ③ 
奏功率 ( %) 78.3 72.5 76.6 
術前評価でCR (件) 4 
病勢制御率 (%) 98.8 98.5 92.8 
DCS療法後の手術 (件) 156 84 166 
*そのうち根治手術 (件) 104 18 60 
組織学的効果判定
Grade 1b以上 (% ) 57.0 52.4 72.7 
Grad巴3 (件) 6 13 
有害事象(Grade3以上)
白血球減少 (%) 33.3 56.1 27.8 
好中球減少 (%) 46.6 56.1 43.6 
発熱性好中球減少症 (% ) 4.1 17.1 0.0 
貧血 (%) 8.5 * 4.0 
食欲不振 (%) 8.7 26.8 5.0 
悪心 (% ) 14.3 * 6.0 











Chemother Pharmacol 2010・6:721-728. 
3) Fushida S， Fujimura T. Feasibility and 
efficacy of preoperative chemotherapy 
with docetaxel， cisplatin and S-l in gastric 
cancer patients with para-aortic lymph nod巴
metastases. Anticancer Drugs 2009; 20: 752-
756. 
4) Hirakawa M， Sato Y. A phase 1 study of 
neoadjuvant combination chemotherapy 
with docetaxel， cisplatin， and S-l for 
1) Koizumi W， Nakayama N. A multic巴nter locally advanced resectable gastric 
phase 1 study of combined chemotherapy cancer:nucleotide excision repair (NER) as 
with docetaxel， cisplatin， and S-l in patients potential chemoresistance marker. Cancer 
with unresectable or recurrent gastric Chemother Pharmacol 2013; 71: 789-797. 
cancer (KDOG0601). Cancer Chemother 5) Fushida S， Nashimoto A. Phase 1 trial of 
Pharmacol 2012; 69: 407-413. preoperative chemotherapy with docetaxel， 
2) Sato y， Takayama T. Phas巴1 study of cisplatin and S-l for T4 locally advanced 
S-l， docetaxel and cisplatin combination gastric cancer. Jpn J Clin Oncol 2012; 42・
chemotherapy in patients with unresectable 131-133 
metastatic gastric cancer. Cancer 6) Katayama H. Ito S. A phase 1 study of 
術前DCS療法でCRが得られた進行胃癌の1例 1 
systemic chemotherapy with docetax巴1，
cisplatin， and S-l (DCS) followed by surgery 
in gastric cancer patients with extensive 
Iymph node metastasis: J apan clinical 
oncology group study JCOGlO02， Jpn J Clin 
Oncol 2012; 42: 556-559. 
7) 原田敬介，信岡隆幸.StageN胃癌に対す
る集学的治療の治療成績 術前Docetaxel/
CDDP / Sl (DCS)療法の有効性一.癌の
臨床 2010;56: 321-327 
8) 浜川卓也，黒川幸典高度進行胃癌に対す
るDocetaxel+Cisplatin +S-l併用療法の治療成
績.癌と化学療法 2011;38: 2342-2344 
9) Yoshikawa T， Rino Y. Neoadjuvant 
chemotherapy for gastric cancer in J apan: 
a standing position by comparing with 
adjuvant chemotherapy. Surg Today 2014; 
4: 11-21. 
